We then developed an AR-positive, ENZ-resistant PDX subline from LuCaP35 CRPC PDX model through consecutive treatments of the tumor-carrying mice with 20 mg/kg ENZ (p.o.) (see SI Appendix, SI Materials and Methods for details). Here, AR is linked to neoplasm.